Drugs / WBF-038
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07044310 | Jul 2025 → Jul 2027 expected | breast carcinoma in situ, female breast carcinoma, hormone receptor-positive breast cancer | Mayo Clinic | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WBF-038 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07044310 ↗ |
| Route | Oral | “Patients receive WBF-038 orally (PO) once daily (QD)” NCT07044310 ↗ |